Search Results

Soligenix, Inc. announced today that the Office of Orphan Products Development of the United States (U.S.) Food and Drug Administration (FDA) has granted orphan drug designation to the active ingredient in MarVax™, the subunit protein vaccine of recombinantly expressed Marburg marburgvirus (MARV) glycoprotein, for “the prevention and post-exposure prophylaxis against MARV infection.”

Public Health Vaccines, LLC (PHV) has started its Phase 1 clinical trial (NCT06265012) to evaluate the safety and immunogenicity of the company’s single-dose vaccine (PHV01) against Marburg virus - a hemorrhagic fever virus of the Filoviridae family that causes Marburg virus disease, a rare but severe hemorrhagic fever that affects people and non-human primates and has a case fatality rate of up to 88%.

The Sabin Vaccine Institute has launched a Phase 2 clinical trial for its vaccine candidate against the lethal Marburg virus.

A Marburg virus vaccine tested at Texas Biomedical Research Institute (Texas Biomed) is progressing in clinical trials, moving a step closer towards becoming the world’s first vaccine against the deadly virus.

Soligenix, Inc. announced today a publication describing the preclinical efficacy of a novel, single-vial, bivalent vaccine providing 100% protection against both Sudan ebolavirus (SUDV) and Marburg marburgvirus (MARV) infections.

Virax Biolabs Group Limited announced today that it has entered into an agreement for the distribution of Marburg Virus PCR testing kits.